“The TALAPRO-2 study showed a significant improvement in overall survival in men with mCRPC treated with the combination of talazoparib and enzalutamide whether they had HRR gene alterations. In this ...

The American Society of Clinical Oncology (ASCO) is a professional oncology society committed to conquering cancer through research, education, prevention, and the delivery of high-quality patient ...

The scholarship application period for the 2025 ASCO Annual Meeting will open on Monday, March 10 at 10:00 AM and close on Monday, March 17 at 5:00 PM (ET). Please read the eligibility and criteria ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Over the last 50 years, research funded by the National Institutes of Health (NIH) and National Cancer Institute (NCI) has played a role in every major advancement related to cancer prevention, ...

Development and validation of a prognostic score for overall survival integrating baseline metabolically active tumor volume measured by 18 F-FDG PET/CT and clinical factors for metastatic colorectal ...

SABRE: Assessment of safety and efficacy of 64 Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.

To learn more about the Oncology Medical Home standards and ASCO Certified recognition from ASCO, please click the button below and submit your questions. ASCO Certified has launched a new application ...